Navigation Links
Royalty Pharma Files Judicial Review Proceedings
Date:6/11/2013

NEW YORK, June 11, 2013 /PRNewswire/ -- Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel requiring it to lapse its Further Increased Offer in the event that the ELND005 Transaction and / or the Share Repurchase Program are approved at the Elan (NYSE: ELN) EGM on 17 June 2013.

Royalty Pharma had requested permission from the Irish Takeover Panel to the effect that it would not be obliged to lapse (withdraw) the Offer in the event that the ELND005 Transaction and / or the Share Repurchase Program were approved at the Elan EGM. On 6 June 2013, the Irish Takeover Panel ruled that Royalty Pharma will be required to lapse the Further Increased Offer in the event that either the ELND005 Transaction and / or the Share Repurchase Program are approved at the Elan EGM.

If Elan shareholders approve either the ELND005 Transaction and / or the Share Repurchase Program, Royalty Pharma is concerned that the Irish Takeover Panel's decision will deprive Elan shareholders of the opportunity to consider Royalty Pharma's Further Increased Offer.

IN ORDER TO ENSURE THAT ELAN SHAREHOLDERS HAVE AN OPPORTUNITY TO CONSIDER ROYALTY PHARMA'S FURTHER INCREASED OFFER, ELAN SHAREHOLDERS ARE URGED TO VOTE "AGAINST" ALL FOUR RESOLUTIONS  PROPOSED BY ELAN AT ITS UPCOMING EGM ON 17 JUNE 2013, INCLUDING THE ELND005 TRANSACTION AND THE SHARE REPURCHASE PROGRAM.  

Royalty Pharma will withdraw these judicial review proceedings if Elan shareholders vote down all four resolutions proposed by Elan at its upcoming EGM on 17 June 2013.

Capitalized terms used but not defined in this announcement have the meaning given to them in Royalty Pharma's Further Revised Offer Document.

J.P. Morgan, together with its affiliate J.P. Morgan Cazenove, BofA Merril
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
2. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
3. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
4. Royalty Pharma Acceptances Announcement
5. Royalty Pharma Responds To Elans Tysabri Valuation
6. Royalty Pharma Response To Elans "Categorical View On Value"
7. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
8. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
11. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report ... Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), ... MarketsandMarkets, the Medical Lifting Sling Market is poised to reach USD ... a CAGR of 11.4 % from 2015 to 2020. ... data T ables and 65 F ...
(Date:8/27/2015)... , Aug. 27, 2015   Proxsys ... Provider (IOPP™) is expanding its population health ... medication-focused transition of care program for hospitals ... Management," provides hospitals with technology systems and ... measures that have been mandated by Center ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... Ontario, Dec. 12, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... the Federal Trade Commission (FTC) voted unanimously to approve the ... dermatology unit of Sanofi (EURONEXT: SAN and NYSE: ... division of Janssen Pharmaceuticals, Inc. As a ...
... PharMEDium announced the first generation solution ... Operating Room (O.R.).  PharMEDium has developed the ... "Our certiMED™ system is designed to be ... Ready-to-Use O.R. syringe medications by providing a visual and ...
Cached Medicine Technology:Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik 2PharMEDium Adds O.R. Medication Verification System 2
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and ... to its cadre of widespread support—an official letter of support and gratitude from the ... community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... West Jordan, Utah (PRWEB) , ... August 28, ... ... has been awarded a three-year accreditation for its adolescent residential, counseling, day treatment ... Academy demonstrates that it meets international standards for quality and its pursuit of ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... use of incense increases the risk of developing cancers of ... analysis, which the authors say is the first prospective investigation ... 2008 issue of CANCER, a peer-reviewed journal of ... of daily life in large parts of Asia. Researchers have ...
... Mich., Aug. 22 Stryker Corporation,(NYSE: SYK ) ... conferences:, September 3, 2008 - 9:45 a.m. ... Boston, Massachusetts, September 17, 2008 - 9:30 ... 2008 London, England, Simultaneous webcasts of the ...
... reduce unhealthy behaviors like binge drinking and eating junk ... But a new study in the Journal of Consumer ... to improve consumer health. , Authors Jonah Berger ... that linking a risky behavior with an "outgroup" (a ...
... hotel towels if they know other guests are doing ... Journal of Consumer Research examined participation rates in ... Authors Noah J. Goldstein (University of Chicago), Robert B. ... that the types of signs posted in hotel bathrooms ...
... Technology approved for control of food-borne pathogens in ... Robert Brackett, chief,science officer for the Grocery ... response to the U.S. Food & Drug,Administration (FDA) ... for,controlling food-borne pathogens in fresh iceberg lettuce and ...
... use eRx Network Medicare Part B transaction ... processing services in its stores nationwide, FORT WORTH, Texas, ... transaction services to the retail pharmacy,industry, announced today that it ... Part B claims, state,Medicaid DME claims and clinical administration programs ...
Cached Medicine News:Health News:Burning incense increases risk of respiratory tract cancers 2Health News:Stryker to Present at Investor Conferences 2Health News:Part of the in-group? A surprising new strategy helps reduce unhealthy behaviors 2Health News:A room with a viewpoint: conservation messages and motivation 2Health News:Grocery Manufacturers Association Strongly Supports U.S. Food & Drug Administration Decision on the Irradiation of Fresh Produce for Foodborne Pathogen Control 2Health News:eRx Network to Provide Transaction Processing and Revenue Cycle Management Services to Rite Aid 2
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
Beta-2 Microglobulin EIA Lipid / Protein Quantification 025-BC-1061...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Human Growth Hormone EIA Endocrine Function 025-BC-1033...
Medicine Products: